Frazier Life Sciences Updates KalVista Pharma Holdings

TL;DR

**Frazier Life Sciences just updated its stake in KalVista Pharmaceuticals, signaling potential shifts in investor influence.**

AI Summary

Frazier Life Sciences Public Fund, L.P. and its affiliates, including Frazier Life Sciences X, L.P. and Frazier Life Sciences XI, L.P., filed an SC 13D/A on February 22, 2024, regarding their ownership in KalVista Pharmaceuticals, Inc. The filing updates their beneficial ownership, which includes a group of individuals like Albert Cha, Daniel Estes, James Brush, and James N. Topper, and various LLCs and LPs associated with Frazier. This amendment reflects changes in their collective holdings in KalVista Pharmaceuticals, Inc. (CIK: 0001348911).

Why It Matters

This filing indicates a change in the ownership structure of KalVista Pharmaceuticals, Inc. by a significant institutional investor group, which can influence company strategy and market perception.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, indicating a change in ownership rather than a new, potentially disruptive event.

Key Players & Entities

• Frazier Life Sciences Public Fund, L.P. (company) — filer
• KalVista Pharmaceuticals, Inc. (company) — subject company
• Albert Cha (person) — group member
• Daniel Estes (person) — group member
• James N. Topper (person) — group member

FAQ

Filing Documents

• d759747dsc13da.htm (SC 13D/A) — 385KB
• 0001193125-24-042587.txt ( ) — 387KB

From the Filing

SC 13D/A 1 d759747dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION W ASHINGTON , D.C. 20549 SCHEDULE 13D U NDER THE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. 4)* Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 20, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 483497103 1. Name of Reporting Persons. Frazier Life Sciences Public Fund, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 1,504,956 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 1,504,956 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,504,956 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 3.6% (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 1,504,956 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on (i) 34,558,709 shares of Common Stock outstanding on November 30, 2023 as set forth in the Issuers Form 10-Q as filed with the SEC on December 7, 2023 and (ii) 7,016,312 shares of Common Stock that were sold on February 20, 2024 by the Issuer to the underwriters in its public offering as described in the Issuers final prospectus filed with the SEC pursuant to Rule 424(b)(5) on February 16, 2024. Page 2 CUSIP No. 483497103 1. Name of Reporting Persons. FHMLSP, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 shares 8. Shared Voting Power 1,504,956 shares (1) 9. Sole Dispositive Power 0 shares 10. Shared Dispositive Power 1,504,956 shares (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 1,504,956 shares (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 3.6% (2) 14. Type of Reporting Person (See Instructions) PN (1) Consists of 1,504,956 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. (2) Based on (i) 34,558,709 shares of Common Stock outstanding on November 30, 2023 as set forth in the Issuers Form 10-Q as filed with the SEC on December 7, 20

View Full Filing

View this SC 13D/A filing on SEC EDGAR